Stayble Therapeutics AB Total Assets
Stayble Therapeutics AB total assets. Based on the latest financial reports, Stayble Therapeutics AB (STABL) holds total assets worth Skr8.62 Million SEK (≈ $927.76K USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see STABL market cap for the company's overall valuation and market capitalisation.
Total Assets of Stayble Therapeutics AB (2016–2025)
Total assets of Stayble Therapeutics AB from 2016 to 2025. This chart illustrates how Stayble Therapeutics AB's total assets have evolved over time, based on quarterly financial data. See Stayble Therapeutics AB stock quote for real-time trading data and today's change.
Stayble Therapeutics AB - Asset Composition Analysis
Stayble Therapeutics AB Total Assets Breakdown (December 2025)
Stayble Therapeutics AB total assets breakdown as of December 2025. Stayble Therapeutics AB's total assets of Skr8.62 Million consist of 34.5% current assets and 65.5% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 28.4% |
| Accounts Receivable | Skr520.00K | 6.0% |
| Inventory | Skr0.00 | 0.0% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr5.65 Million | 65.5% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Stayble Therapeutics AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Stayble Therapeutics AB current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Stayble Therapeutics AB's current assets represent 34.5% of total assets in 2025, a decrease from 69.4% in 2016.
- Cash Position: Cash and equivalents constituted 28.4% of total assets in 2025, down from 65.7% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 65.0% of total assets, an increase from 2.0% in 2016.
- Asset Diversification: The largest asset category is intangible assets at 65.5% of total assets.
Stayble Therapeutics AB Competitors by Total Assets
Key competitors of Stayble Therapeutics AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Stayble Therapeutics AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.50 | 2.35 | 33.55 |
| Quick Ratio | 3.50 | 2.35 | 33.55 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr2.12 Million | Skr2.07 Million | Skr45.21 Million |
Stayble Therapeutics AB - Advanced Valuation Insights
This section examines the relationship between Stayble Therapeutics AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 3.05 |
| Latest Market Cap to Assets Ratio | 0.16 |
| Asset Growth Rate (YoY) | -6.9% |
| Total Assets | Skr8.62 Million |
| Market Capitalization | $1.42 Million USD |
Valuation Analysis
Below Book Valuation: The market values Stayble Therapeutics AB's assets below their book value (0.16x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Stayble Therapeutics AB's assets decreased by 6.9% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Stayble Therapeutics AB (2016–2025)
The table below shows the annual total assets of Stayble Therapeutics AB from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr8.62 Million ≈ $927.76K |
-6.87% |
| 2024-12-31 | Skr9.26 Million ≈ $996.20K |
-57.35% |
| 2023-12-31 | Skr21.70 Million ≈ $2.34 Million |
+13.35% |
| 2022-12-31 | Skr19.15 Million ≈ $2.06 Million |
-56.12% |
| 2021-12-31 | Skr43.64 Million ≈ $4.70 Million |
+142.48% |
| 2020-12-31 | Skr18.00 Million ≈ $1.94 Million |
+85.17% |
| 2019-12-31 | Skr9.72 Million ≈ $1.05 Million |
+7.95% |
| 2018-12-31 | Skr9.00 Million ≈ $968.92K |
-4.81% |
| 2017-12-31 | Skr9.46 Million ≈ $1.02 Million |
-22.22% |
| 2016-12-31 | Skr12.16 Million ≈ $1.31 Million |
-- |
About Stayble Therapeutics AB
Stayble Therapeutics AB (publ) a clinical pharmaceutical company, developing an injection-based treatments for disc herniation. It develops STA363, an injection into the disc that targets chronic low back and leg pain. The company was incorporated in 2015 and is based in Gothenburg, Sweden.